Overton FDA Hearing Tests Scientific Independence

Heidi Overton’s FDA confirmation hearing put a wider regulatory question under the Senate spotlight: How much independent scientific, clinical, patient, and public input should shape decisions in the U.S. Food and Drug Administration (FDA)? 

Image

Advisory Committees Are Part of the Regulatory Infrastructure

Heidi Overton’s FDA confirmation hearing on 24 September exposed the fault lines running through American drug and tobacco policy.

Senators pressed President Trump’s nominee on vaccines, the abortion pill, and vaping, while the agency she hopes to lead has quietly lost more than a quarter of its outside independent scientific committees.

For pharma, the hearing was less about one nominee and more about who is now allowed to challenge the FDA’s decisions and MAHA’s agenda.

The hearing came after major changes across the Department of Health and Human Services (HHS), including terminated advisory committees, cancelled research grants, reduced agency capacity, and a more contested approach to vaccines, tobacco products, and reproductive health.

The scale of change across the HHS is larger than the FDA alone.

A Public Citizen analysis found that at least 75 federal health advisory committees were shut down in 2025, with 49 axed at the National Institutes of Health alone.

Public health reporting from the American Public Health Association put the FDA’s own losses in a similar range, warning that roughly a quarter of its expert panels had disappeared within a single year. That included 49 NIH committees, nine CDC committees, and four FDA committees.

Some of the important independent committees terminated include the Arthritis Advisory Committee, Medical Imaging Drugs Advisory Committee,  and the Patient Engagement Advisory Committee, amongst many many others.

The reduction was also visible in FDA activity. Advisory committees held 41 meeting days across 20 committees in 2024. In 2025, that fell to just 15 meeting days across nine committees, a 63% reduction.

While these bodies do not replace FDA decision-makers, they do provide external scrutiny around difficult scientific, technical, and public health questions.

The FDA itself describes advisory committees as a source of independent advice from scientists, clinicians, statisticians, consumers and patients. Their recommendations are non-binding, while final decisions remain with the agency.

The patient role is particularly important. The FDA established its Patient Engagement Advisory Committee to bring patients, caregivers, and patient organisations into discussions about medical-device regulation, clinical investigations, real-world evidence, benefit-risk communication, and patient experience.

Removing or reducing that patient channel changes who is present when complex regulatory questions are debated.

There is also a legal and governance dimension. A 2026 JAMA Health Forum analysis compared traditional FDA advisory committees with newer expert panels. The authors noted that traditional committees have ongoing membership, conflict-of-interest screening, collective discussion, and formal recommendations under the Federal Advisory Committee Act.

The newer panels are typically one-off meetings without the same structure. The FDA describes its expert panels as independent scientific roundtables, but the difference in process is material.

For industry, this is not simply a question of political optics. Independent review can expose weak evidence, identify missing subgroups, challenge assumptions, and improve the credibility of a difficult decision.

A sponsor may prefer a predictable process, but predictability depends on the regulator being trusted by patients, investors, clinicians, and other companies.

The Cost of a Hollowed-Out Advisory System

As discussed, Heidi Overton’s FDA confirmation hearing did not happen in a vacuum. Before senators asked her a single question, the agency’s outside advisory system had already been hollowed out.

The cuts reach beyond formal committees.

At the Centers for Disease Control and Prevention, nine advisory panels were dissolved, including the committee that set hand hygiene and surgical safety standards for hospitals and the group responsible for setting immunisation policy.

The Dietary Guidelines Advisory Committee vanished before new nutrition recommendations were issued in January, removing the scientific consensus step that normally precedes such guidance.

In summary:

• At least 75 HHS advisory committees were terminated in 2025, including 49 at the NIH.
• Nine CDC advisory panels were dissolved, among them the Healthcare Infection Control Practices Advisory Committee.
• Two key food safety panels, the U.S. Department of Agriculture’s (USDA’s) National Advisory Committee on Microbiological Criteria for Foods (NACMCF) and National Advisory Committee on Meat and Poultry Inspection (NACMPI), were closed entirely.
• FDA leadership moved to sideline individual drug advisory meetings, holding just seven such sessions across all of 2025.

Image

The committee cuts sit alongside deep funding fights.

Before being rejected by Congress, the Trump administration’s fiscal year 2026 budget proposed cutting the FDA’s operating funds by more than 11 per cent and the NIH by around 40%.

Democratic Senator Patty Murray said the FDA reduction was “not going to fly” during Former Commissioner Makary's own budget testimony, and Senator Dick Durbin used a separate appropriations hearing to accuse the administration of decimating the medical research funding that supports new cancer and Alzheimer's treatments.

Public health researchers argue the consequences are already visible.

Critics of the roundtable panels the FDA has used in place of some terminated committees say the process has helped justify removing long-standing box warnings on menopausal hormone products, despite the underlying safety data not changing.

Researchers writing in the American Public Health Association’s own publication warned of a widening brain drain as scientists leave their fields entirely rather than work without an outside review mechanism, leaving agencies to rely on narrower information when writing rules that affect millions of patients.

For sponsors, a thinner advisory bench cuts both ways.

Fewer public hearings can speed reviews along, but they also remove an independent check that has historically protected sound approvals from political reversal further down the line.

View interview How AI Is Opening New Opportunities in Fertility Care for Pharma

How AI Is Opening New Opportunities in Fertility Care for Pharma

"If I had to get great minds in a room, I'd be looking at it from a tech perspective. How can we take all this knowledge, apply it to policies that can be easily distributed?” Clara Toombs, Fertilia AI.

Image

Grants, Budgets, and the Cost of Losing Research Capacity

The funding story is equally significant.

A peer-reviewed JAMA study identified 694 NIH grants terminated between 28 February and 8 April 2025, representing $1.81 billion in grant funding.

About $544 million remained unspent when those awards were terminated. The terminations affected 24 of 26 NIH institutes and centres with active grants in the study period.

The U.S. Government Accountability Office (GAO) subsequently concluded that the NIH had terminated more than 1,800 grants between February and June 2025 and found that HHS had violated the Impoundment Control Act by withholding congressionally appropriated funds.

The administration also proposed much larger reductions through the federal budget process.

The FY2027 request sought about $41.4 billion from the NIH, around $5.5 billion below FY2026 enacted funding, while proposing major structural changes to the institute system.

The proposal also sought substantial reductions for CDC and other health agencies. These are proposals, not enacted appropriations, and Congress ultimately controls federal spending.

A cancelled grant can terminate a research programme immediately, while a budget proposal can alter investment expectations before it becomes law.

Together, they can also affect the research workforce, clinical-trial infrastructure, university partnerships, and the supply of early-stage discoveries that eventually feed commercial pipelines.

The consequences cannot be overstated.

There is no reliable model that can translate the loss of advisory meetings or cancelled grants into a precise number of future illnesses or deaths.

But the causal pathways are well understood.

Less research can mean fewer validated hypotheses, slower development of diagnostics and therapies, weaker disease surveillance, and fewer trained investigators.

Less independent regulatory input can also reduce the diversity of evidence considered before high-impact decisions.

That is why the issue reaches beyond Washington D.C.

The Association of American Medical Colleges (AAMC) has warned that reductions in NIH support will slow scientific progress and deprive patients and communities of new treatments, diagnostics, and preventive interventions.

The organisation also reported that more than 1,100 NIH grants had been terminated by June 2025, including at least 160 clinical trials.

For a pharmaceutical industry that depends on a long research horizon, the risk is cumulative. The loss of one grant or one committee meeting rarely changes an entire field. Repeated reductions can.

How Makary’s Exit Opened the Door for Big Tobacco

Overton’s confirmatory hearing also sits in the shadow of her predecessor’s exit.

Marty Makary resigned as FDA commissioner in May 2026, after allegedly resisting pressure to approve fruit-flavoured vapes, according to KFF Health News reporting on the events that followed.

The sequence, as reported, moved quickly. Reynolds American, the maker of Camel and Lucky Strike, allegedly gave U.S.D. $5 million to a pro-Trump super PAC on 30 April.

Two days later, tobacco executives met President Trump at his Florida golf club allegedly to raise concerns about the FDA’s flavoured-vape restrictions. The Trump administration confirms  that thereafter on the same day, the President had a five minute phone call with a senior FDA official.

Then, within a week the agency authorised the first mango and blueberry vape flavours ever cleared for sale in the United States.

Tobacco interests have allegedly now given Trump-aligned political committees more than $20 million since 2025, and Altria and Reynolds have both offered donations toward Trump’s $400 million White House ballroom project, according to the same reporting.

Government watchdogs and public health groups have called the timing troubling, while the administration has said there is no evidence linking the donation to the policy change.

Overton inherits this legacy directly now.

At her hearing, she pointed out that several flavoured vapes already had backing from FDA scientists as tools to help adult smokers quit, but she gave no clear answer on whether she would maintain the tighter restrictions that existed before Makary’s departure.

Read Maximise Pharma Innovation With Quality-by-Design

Maximise Pharma Innovation With Quality-by-Design

Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.

Image

Makary, Vapes, and the Tobacco Question

As discussed, the Overton hearing also needs to be read against the events surrounding former FDA Commissioner Marty Makary.

Makary resigned on 12 May 2026, after a period of reported tension within the administration.

Reporting linked the dispute to several issues, including flavored e-cigarettes and the FDA’s handling of the oral contraceptive mifepristone.

The vaping controversy became especially significant because the FDA changed its enforcement approach in May.

On 5 May 2026, the agency authorised four Glas electronic nicotine delivery systems, including non-tobacco and non-menthol variants, subject to restrictions.

Three days later, the FDA issued guidance describing enforcement priorities for certain unauthorised electronic nicotine delivery systems and nicotine pouches.

The scientific debate is more complicated than either side of the political argument.

A 2025 umbrella review in Tobacco Control found a consistent association between youth vaping and later cigarette smoking initiation across many reviews.

At the same time, the evidence base on flavoured versus unflavoured products was more limited. A 2026 Cochrane review also found high-certainty evidence that nicotine e-cigarettes increase smoking cessation compared with nicotine replacement therapy, while noting that longer-term safety remains uncertain.

That tension explains why the FDA’s process matters. A regulatory decision has to weigh potential adult smoking-cessation benefits against youth initiation, nicotine dependence, and other population-level risks.

The financial context intensified scrutiny.

KFF Health News reported that Reynolds American contributed U.S.D. $5 million to MAGA Inc. on 30 April 2026, shortly before the FDA’s May vaping actions.

It also reported that President Trump held tobacco-company investments and that he had several meetings with representatives for flavoured vapes leading up to the big controversial changes and that tobacco interests had made substantial political contributions.

A Senate Finance Committee investigation separately documented the 30 April contribution and a 2nd of May meeting between Trump and Reynolds executives, while alleging that the executives raised complaints about FDA regulation.

Those facts establish timing, financial relationships, and access. They do not, by themselves, establish that a regulatory decision was exchanged for a political contribution.

But that distinction matters for a regulator whose legitimacy depends on evidence-based decision-making.

Image

Vaccines and Women’s Health Put the FDA Test Into Sharp Focus

Vaccines produced the clearest scientific test at the Overton hearing.

Overton told senators that the measles, mumps, and rubella (MMR) vaccine is safe and effective and that vaccines currently recommended in the United States are safe and effective.

But, she also declined to say directly that President Trump was wrong to support changes to the childhood vaccination schedule or to repeat claims about vaccine safety.

The evidence base is considerably clearer than the political debate.

A September 2026 World Health Organization systematic review covering peer-reviewed research from 2010 through August 2025 found that the most methodologically rigorous studies do not support a causal association between vaccines and autism.

CDC guidance states that two doses of MMR are 97% effective against measles.

For FDA leadership, the issue is that regulatory decisions continue to be anchored in reproducible evidence, transparent review, and appropriate external expertise.

The same question arose over mifepristone.

During the hearing, Overton said the drug had met FDA safety and efficacy standards but did not give senators the direct personal assurance they sought.

Her previous public writing on abortion policy also became part of the questioning.

Here again, the underlying evidence provides an important reference point.

An NEJM population study covering more than 195,183 abortions in Ontario found no material change in severe adverse events or complications after mifepristone became available without prescription restrictions.

A 2025 BMJ systematic review of six studies involving 54,233 women found no difference in effectiveness between home and clinic administration.

The FDA is nevertheless conducting a further safety study and says it intends to complete the work with appropriate data analysis, integrity checks, and peer review. However, many feel that this review is more about politics than science.

Regardless, that means a future FDA commissioner will have to manage both the scientific evidence already available and the agency’s ongoing regulatory review.

For the pharmaceutical sector, these issues converge on one principle: Regulatory credibility is an operational asset.

Companies need decisions that are scientifically defensible, transparent enough to withstand scrutiny, and stable enough to support long-term investment.

Overton’s FDA hearing therefore matters beyond the nominee.

It exposed the institutional questions now facing the FDA. Who provides independent advice, how research is funded, how patient voices enter regulatory deliberation, and whether politically sensitive products receive the same evidence-based scrutiny as everything else.

Vaccines and Women’s Health Under Scrutiny

As discussed, vaccines dominated much of the questioning. Overton called MMR “safe and effective”.

Yet she declined to say that Trump was wrong when he called the same vaccine potentially “lethal” during an August Oval Office appearance. Senators noted that Overton had not corrected him at the time.

On mifepristone, the abortion pill approved for use in 2000, Overton confirmed the drug had met the FDA’s safety and efficacy standard, but repeatedly declined to give her own opinion of its safety, as Axios reported after the hearing.

Democratic Senator Maggie Hassan reminded her of a 2023 policy paper, co-written for a conservative think tank, in which Overton described medication abortion as dangerous to women.

The stakes are high.

If confirmed, Overton would oversee the FDA’s ongoing safety review of mifepristone's risk evaluation and mitigation strategy, the framework that currently allows the pill to be prescribed by telemedicine and shipped by mail.

Republican Senator Lisa Murkowski, a pivotal vote on the committee, said she was concerned about political pressure to revisit the approval status of established products.

In summary:

• For the MMR vaccine: Called safe and effective, but no comment on President Trump’s “lethal” claim
• Mifepristone: Confirmed it met FDA standards, but offered no personal opinion

• REMS review: An ongoing safety study into telemedicine dispensing, with the outcome undecided

  Image

  

What Does a Different ‘Overton Window’ Mean for Pharma?

Overton’s FDA confirmation hearing exposed a regulatory system under competing pressures.

The questions were not limited to one nominee or one administration. They reached into the infrastructure that supports pharmaceutical decision-making, from scientific advisory committees and public research funding to patient participation and evidence review.

For the pharma industry, the hearing exposed unanswered questions of whether advisory committees will be reinstated for contested drug reviews, or will companies increasingly negotiate with agency leadership alone.

Further, will the mifepristone review reshape a reproductive health market worth billions.

In pharma, the central issue is always regulatory confidence. Companies need clear standards, consistent scientific review, and credible institutions. They also need confidence that complex decisions can withstand scrutiny from clinicians, researchers, patients and the wider public.

The Senate HELP Committee still has to vote before her nomination reaches the full chamber.

At Pharmatica, we track the systems, standards, and enforcement patterns shaping pharmaceutical regulation, connecting leadership changes like this one to the decisions that follow. Explore our Regulatory Insights for ongoing coverage of the FDA's next chapter.

Pharmatica: Insight. Connection. Impact.